Tag: Lung Cancer
TRACKER: Australia’s First Longitudinal Biobank for Advanced Lung Cancer
The creation of Australia's first Longitudinal Biobank, a collaborative effort between Austin Health and leading research institutions, aims to establish an extensive biorepository of biological...
OncoHost Collaborates with Lung Biobank Heidelberg to Discover Lung Cancer Biomarkers
OncoHost, a global leader in next-generation precision oncology for improved personalized cancer therapy, recently announced a research collaboration with Lung Biobank Heidelberg, a member...
Biodesix to Collaborate with Datavant to Boost Value of Lung Cancer Databank
Biodesix, Inc. (Nasdaq: BDSX), a leading lung cancer diagnostic solutions company, announced a strategic partnership with Datavant, a leader in helping healthcare organizations safely connect their...
Neutrophil Defensin Expression Correlated With Immune Checkpoint Response In Lung Cancer
Lung cancer is the leading cause of cancer related death. Non-small cell lung cancer (NSCLC), comprises 80–85% of all lung cancer cases. Programmed cell...
CLOVER Study Of PDL1 In NSCLC Demonstrates PCR RNA Expression Analysis Not Equivalent To...
Programmed cell death ligand 1 (PDL1) is approved therapeutic target in lung cancer patients. PDL1 expression above a set threshold must be confirmed by...
A Living Biobank Of Non-Small Cell Lung Cancer Organoids
Globally, cancer of the lung is the most common cause of
cancer related mortality. It is also the most commonly diagnosed. 3D patient derived
organoids provide...
Biobank Study Of Functional Lung Impairment And Lung Cancer Risk
Globally, cancer of the lung is the most common cause of
cancer related mortality. It is also the most commonly diagnosed. Tobacco smoke
is a well-known...
Veracyte Makes Progress With Development Of Nasal Swab Test For Early Lung Cancer Detection
Veracyte, Inc. has announced preliminary clinical data
showing that the company’s non-invasive nasal swab test – the first of its kind
– can enable early lung...
Veracyte Releases Percepta® Genomic Sequencing Classifier For Lung Cancer Diagnosis
Veracyte, Inc., a leading genomic diagnostics company, has
begun making its next-generation Percepta® Genomic Sequencing Classifier (GSC)
available to physicians, providing them with expanded lung cancer...
Veracyte and Johnson & Johnson Collaborate To Pool Resources For The Lung Cancer Initiative
Veracyte, Inc. has announced that it has entered into a
long-term strategic collaboration with Johnson & Johnson Innovation LLC (Johnson
& Johnson Services, Inc.) and the...



















